Arnold KA - Search Results

1

Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor.

Arnold KA, Eichelbaum M, Burk O. Arnold KA, et al. Nucl Recept. 2004 Mar 25;2(1):1. doi: 10.1186/1478-1336-2-1. Nucl Recept. 2004. PMID: 15043764 Free PMC article.

2

A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression.

Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. Burk O, et al. Among authors: arnold ka. Biol Chem. 2005 Jun;386(6):503-13. doi: 10.1515/BC.2005.060. Biol Chem. 2005. PMID: 16006237

3

Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M. Burk O, et al. Among authors: arnold ka. Mol Pharmacol. 2005 Jun;67(6):1954-65. doi: 10.1124/mol.104.009019. Epub 2005 Mar 10. Mol Pharmacol. 2005. PMID: 15761118

4

Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.

Kivistö KT, Grisk O, Hofmann U, Meissner K, Möritz KU, Ritter C, Arnold KA, Lutjöohann D, von Bergmann K, Klöting I, Eichelbaum M, Kroemer HK. Kivistö KT, et al. Among authors: arnold ka. Drug Metab Dispos. 2005 Nov;33(11):1593-6. doi: 10.1124/dmd.105.006262. Epub 2005 Aug 17. Drug Metab Dispos. 2005. PMID: 16107564

5

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. Igel M, et al. Among authors: arnold ka. Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11. Clin Pharmacol Ther. 2006. PMID: 16678544 Clinical Trial.

6

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.

Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T. Niemi M, et al. Among authors: arnold ka. Pharmacogenet Genomics. 2006 Nov;16(11):801-8. doi: 10.1097/01.fpc.0000230422.50962.91. Pharmacogenet Genomics. 2006. PMID: 17047488

7

The rate of decline of diphenylhydantoin in human plasma.

Arnold K, Gerber N. Arnold K, et al. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121-34. doi: 10.1002/cpt1970111121. Clin Pharmacol Ther. 1970. PMID: 5410894 No abstract available.

8

Studies on the metabolism of diphenylhydantoin in mice.

Gerber N, Arnold K. Gerber N, et al. J Pharmacol Exp Ther. 1969 May;167(1):77-90. J Pharmacol Exp Ther. 1969. PMID: 5772752 No abstract available.

9

The effect of diphenyl-piperazine compounds and other agents on diphenylhydantoin, zoxazolamine and hexobarbital metabolism.

Gerber N, Arnold K. Gerber N, et al. J Pharmacol Exp Ther. 1968 Nov;164(1):232-8. J Pharmacol Exp Ther. 1968. PMID: 4387047 No abstract available.

10

The bright and dark sides of employee mindfulness: Leadership style and employee well-being.

Walsh MM, Arnold KA. Walsh MM, et al. Among authors: arnold ka. Stress Health. 2020 Aug;36(3):287-298. doi: 10.1002/smi.2926. Epub 2020 Feb 11. Stress Health. 2020. PMID: 31957962

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results